NCT04795726 - A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy, DR) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 10, 2021

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions

Diabetic Retinopathy

Interventions

DRUG

Finerenone (BAY94-8862)

10 mg or 20 mg Finerenone tablet to be given orally, once daily, administered in the FIDELIO-DKD or FIGARO-DKD clinical trial.

DRUG

Placebo

Matching placebo to be taken orally, once daily, administered in the FIDELIO-DKD or FIGARO-DKD clinical trial.

Trial Locations (11)

DCC Aleksandrovska, Sofia

MHAT Sveta Karidad, Plovdiv

MHAT Dr. Bratan Shukerov AD, Smolyan

MCOMH Preventsia-2000, Stara Zagora

Med Centre Diamedical 2013, Dimitrovgrad

MHAT Sveti Pantaleymon - Yambol, Yambol

MHAT Hadzhi Dimitar, Sliven

Southmead Hospital, Bristol

St Richard's Hospital, Chichester

Royal London Hospital, London

King's College Hospital - NHS Foundation Trust, London